In a recent press release, biotechnology company Leading Edge Farms, Inc. reported that it is partnering with Mr. Checkout, a national group of independent distributors with a multitude of distribution channels. Leading Edge Farms is a company that develops cannabinoid therapies provided through innovative delivery systems, while Mr. Checkout has distribution channels at corporate c-stores, box stores, independent retailers, grocers, and more.
Through the partnership, Leading Edge Farms will be able to make available its pain and inflammation relief products to checkout networks in over 35,000 stores throughout the United States, according to the press release.
Joel Goldstein, Mr. Checkout’s CEO, shared in the press release,
“Quality CBD products can be challenging to find in a market that is flooded with options – some reliable and others making unfounded claims. Consumers don't know which brands to trust.” He added.
“Working with Leading Edge means consumers receive access to reliable, tested CBD pain relief products. We feel confident distributing the CANNAVERA line to thousands of retailers across the United States.”
David Chadwick, the CEO of Leading Edge, also shared in the press release,
“One major advantage of Leading Edge's CANNAVERA products is that they are non-systemic and therefore can be sold nationwide, across state borders, in their current form.” He continued,
“Partnering with Mr. Checkout, with its vast distribution network, allows our products to reach even more consumers seeking natural and effective pain relief, marking a new chapter for us during our continued growth.”
Leading Edge is recognized for its CBD-based topical formulas that have been developed with Silvidol, which is a compound developed by the company. The compound is proprietary and non-systemic. Its presence in the brand’s products enable it to provide targeted pain and inflammation relief, and a better delivery system. Further, the brand’s products are manufactured in facilities that follow the FDA’s cGMP manufacturing standards.